Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
Authors
Keywords
-
Journal
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Volume 17, Issue 3-4, Pages 229-239
Publisher
Springer Nature
Online
2012-09-26
DOI
10.1007/s10911-012-9266-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients
- (2015) Jeanine M. Roodhart et al. NEOPLASIA
- Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
- (2012) Silvia Dellapasqua et al. BREAST
- Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report
- (2012) Gaetano Aurilio et al. Breast Journal
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney
- (2012) Brian Rini et al. CANCER
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
- (2012) Farbod Shojaei et al. CANCER LETTERS
- Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
- (2012) John R. Mackey et al. CANCER TREATMENT REVIEWS
- Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
- (2012) V. Moreno Garcia et al. CLINICAL CANCER RESEARCH
- Bevacizumab and breast cancer: what does the future hold?
- (2012) Christina E Stevenson et al. Future Oncology
- Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
- (2012) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Avastin Saga Reveals Debate Over Clinical Trial Endpoints
- (2012) S. P. Sharma JNCI-Journal of the National Cancer Institute
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- Bevacizumab in Ovarian Cancer
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Fighting Fire with Fire: Rekindling the Bevacizumab Debate
- (2012) Alberto J. Montero et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
- (2012) M. Martin et al. ONCOLOGIST
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
- (2012) Christoph Thomssen et al. ONCOLOGY
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
- (2012) Melissa Taylor et al. Cancer Discovery
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
- (2011) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study
- (2011) Kenjiro Aogi et al. BREAST CANCER RESEARCH AND TREATMENT
- The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy
- (2011) Shaheenah Dawood et al. CANCER
- Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy
- (2011) B. Sitohy et al. CANCER RESEARCH
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
- (2011) Denise A. Yardley et al. Clinical Breast Cancer
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
- (2011) Xavier Pivot et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab Treatment for Solid Tumors
- (2011) Daniel F. Hayes JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies
- (2011) Marc Buyse et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Avastin's Uncertain Future in Breast Cancer Treatment
- (2011) R. Twombly JNCI-Journal of the National Cancer Institute
- Avastin Hearing Leads to More Uncertainty Over Drug's Future
- (2011) M. Goozner JNCI-Journal of the National Cancer Institute
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Miguel Martin et al. LANCET ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Reputation and Precedent in the Bevacizumab Decision
- (2011) Daniel Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
- (2011) S. Verma et al. ONCOLOGIST
- An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity
- (2011) O. Mir et al. ONCOLOGIST
- Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
- (2011) Alberto J. Montero et al. Current Oncology Reports
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
- (2010) I. E. Smith et al. ANNALS OF ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
- (2010) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
- (2010) Iris Helfrich et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Raising the bar for cancer therapy models
- (2010) Giulio Francia et al. NATURE BIOTECHNOLOGY
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
- (2009) A. Rapisarda et al. MOLECULAR CANCER THERAPEUTICS
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
- (2008) H. J. Burstein et al. CLINICAL CANCER RESEARCH
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now